Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750334 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00750334 is a Phase 1 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 2 participants.
The verdict
NCT00750334, a Phase 1 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
Interventions
- DRUG clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750334
The ClinicalTrials.gov registry entry for NCT00750334 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clofarabine is the first listed.
NCT00750334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750334 about?
NCT00750334 is a clinical study titled "A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)". This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
What is the current status of trial NCT00750334?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00750334?
The interventions under investigation include: clofarabine (DRUG).
Who is sponsoring clinical trial NCT00750334?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.